Phase IIB Clinical Trial of Voclosporin Successfully Achieves Primary Endpoint

Good news posted yesterday on the Lupus Foundation of America website. To see the full article please click here.

“(Washington DC – August 15)  Today Aurinia Pharmaceutical Company announced positive top-line results of a Phase IIB clinical study of voclosporin, a potential new therapy option for people with active lupus nephritis (lupus-related kidney disease).  The study met its primary endpoint of achieving complete remission in a statistically significant number of study participants who received voclosporin. More details about this study are available through the company’s news release.

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
5 days ago
LUPUS EUROPE

As much as we love hearing from you all and appreciate the time you take to share how you #kicklupus and inspire others, we cannot allow any content specifically about healing products for lupus.

We would greatly appreciate if you followed this rule when posting on the page.
Thank you
... See MoreSee Less

1 week ago
LUPUS EUROPE

#WorldLupusDay finishes today, but #lupusawareness does not. There is so much more we can do to make life with #lupus better. Watch our vice chair, Anne Charlet, talk about her journey of becoming a Board Member.
You can also join us and become a volunteer
... See MoreSee Less

Comment on Facebook

Wauvvvv SO good looking :-)

LUPUS EUROPE Uniting people with Lupus throughout Europe
Send